They are not paying Advent ultimately. The Specials Program is for drugs that are not yet licensed. Further, the cost of manufacturing at commercial scale to do this is not insignificant. And the reality is, this pays initially the cost of being fully commercially licensed and fully operational (you can’t have one without the other). Further, if that revenue were not paying that cost, NWBO would be paying it, which means the burn rate would be much, much higher and the dilution therefore. So yeah, NWBO benefits directly, and so do we. But it is not a pre-approval marketing program. Further, if revenue reaches the level where it effectively created an actual profit overall, NWBO would get that also, and likely at some point demand hits that point. But it has always been doubtful it would hit that point a few months after full licensing.
News 
Market Data 
Discover 
